Sanofi - ADR (SNY): Price and Financial Metrics


Sanofi - ADR (SNY): $48.57

0.08 (+0.16%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SNY POWR Grades

  • SNY scores best on the Value dimension, with a Value rank ahead of 93.31% of US stocks.
  • The strongest trend for SNY is in Quality, which has been heading down over the past 177 days.
  • SNY ranks lowest in Momentum; there it ranks in the 22nd percentile.

SNY Stock Summary

  • With a market capitalization of $123,348,795,046, SANOFI has a greater market value than 98.28% of US stocks.
  • With a year-over-year growth in debt of -26.85%, SANOFI's debt growth rate surpasses just 11.49% of about US stocks.
  • As for revenue growth, note that SNY's revenue has grown -4.24% over the past 12 months; that beats the revenue growth of just 18.75% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to SANOFI are DE, CAT, BMY, GILD, and IBM.
  • SNY's SEC filings can be seen here. And to visit SANOFI's official web site, go to www.sanofi.com.

SNY Stock Price Chart Interactive Chart >

Price chart for SNY

SNY Price/Volume Stats

Current price $48.57 52-week high $58.10
Prev. close $48.49 52-week low $36.91
Day low $48.48 Volume 2,061,900
Day high $49.09 Avg. volume 2,502,595
50-day MA $47.40 Dividend yield 2.6%
200-day MA $46.99 Market Cap 123.12B

Sanofi - ADR (SNY) Company Bio


Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. The company was founded in 1973 and is based in Paris, France.


SNY Latest News Stream


Event/Time News Detail
Loading, please wait...

SNY Latest Social Stream


Loading social stream, please wait...

View Full SNY Social Stream

Latest SNY News From Around the Web

Below are the latest news stories about SANOFI that investors may wish to consider to help them evaluate SNY as an investment opportunity.

Sanofi offers VRS to 800 staffers at India vaccine units amid review

The drugmaker is offering voluntary retirement scheme (VRS) to all its employees at two sites near Hyderabad

Business Standard | January 30, 2023

Sanofi to let go off staff in India

French drugmaker Sanofi SA is reviewing operations at two of its vaccine making facilities in India and plans to let go of all employees at the plants, the company told Reuters, after it failed to win a UNICEF contract. The drugmaker is offering voluntary retirement scheme (VRS) to all its employees at two sites near Hyderabad, a spokesperson for Sanofi''s India unit told Reuters in an email. About 800 employees could be affected by the decision, two sources familiar with the matter said. The sources did not want to be named as the matter is confidential. Sanofi India declined to comment on the number of employees who would be offered VRS. The French company has over 5,000 employees in India, according to its website. The two plants manufacture vaccines against hepatitis B, diphtheria a...

Economic Times India | January 30, 2023

Sanofi, Regeneron Dupixent gets approval in EU for expanded use in eosinophilic esophagitis

The European Commission ((EC)) approved Sanofi (SNY) and Regeneron Pharmaceuticals'' (REGN) Dupixent to treat eosinophilic esophagitis (EoE) in patients 12 years and older, weighing…

Seeking Alpha | January 30, 2023

Drugmakers prevail in dispute over U.S. discount drug program

Drug manufacturers can limit healthcare providers’ use of outside pharmacies for dispensing drugs under a federal drug discount program, a federal appeals court ruled Monday. The ruling from a three-judge panel of the 3rd U.S. Circuit Court of Appeals based in Philadelphia is a victory for Sanofi SA, Novo Nordisk AS and AstraZeneca PLc . […]

Financial Post | January 30, 2023

Sanofi to let go off staff at vaccine plants in India as part of review

French drugmaker Sanofi SA is reviewing operations at two of its vaccine making facilities in India and plans to let go of all employees at the plants, the company told Reuters, after it failed to win a UNICEF contract. The drugmaker is offering voluntary retirement scheme (VRS) to all its employees at two sites near […]

Financial Post | January 30, 2023

Read More 'SNY' Stories Here

SNY Price Returns

1-mo 0.29%
3-mo 13.11%
6-mo -1.24%
1-year -4.34%
3-year 8.41%
5-year 31.94%
YTD 0.29%
2022 -1.00%
2021 5.87%
2020 -0.83%
2019 23.73%
2018 4.20%

SNY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full SNY Dividend History

Continue Researching SNY

Want to see what other sources are saying about Sanofi's financials and stock price? Try the links below:

Sanofi (SNY) Stock Price | Nasdaq
Sanofi (SNY) Stock Quote, History and News - Yahoo Finance
Sanofi (SNY) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.735 seconds.